Atea Pharmaceuticals (AVIR) Operating Expenses: 2019-2024
Historic Operating Expenses for Atea Pharmaceuticals (AVIR) over the last 6 years, with Dec 2024 value amounting to $192.9 million.
- Atea Pharmaceuticals' Operating Expenses fell 43.80% to $39.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was $130.7 million, marking a year-over-year decrease of 38.66%. This contributed to the annual value of $192.9 million for FY2024, which is 17.54% up from last year.
- Per Atea Pharmaceuticals' latest filing, its Operating Expenses stood at $192.9 million for FY2024, which was up 17.54% from $164.2 million recorded in FY2023.
- Atea Pharmaceuticals' Operating Expenses' 5-year high stood at $213.0 million during FY2021, with a 5-year trough of $59.7 million in FY2020.
- In the last 3 years, Atea Pharmaceuticals' Operating Expenses had a median value of $164.2 million in 2023 and averaged $162.6 million.
- Per our database at Business Quant, Atea Pharmaceuticals' Operating Expenses soared by 308.43% in 2020 and then slumped by 38.66% in 2022.
- Atea Pharmaceuticals' Operating Expenses (Yearly) stood at $59.7 million in 2020, then skyrocketed by 256.99% to $213.0 million in 2021, then plummeted by 38.66% to $130.7 million in 2022, then rose by 25.65% to $164.2 million in 2023, then climbed by 17.54% to $192.9 million in 2024.